drugset / Trial / NCT00237653

MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus

NCT00237653

Phase 3 Terminated 40 enrolled University Hospital, Grenoble
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of this study is to demonstrate the relevance of Valganciclovir on recurrent bouts of cryptogenic inflammatory bowel diseases with infection by cytomegalovirus (CMV). The goal is to obtain 90% (for Valganciclovir treated patients) versus 50% (for placebo treated patients) remission at 3 months (including the discontinuation of corticoids or reducing their dose to under 20 mg of prednisone equivalence), without any relapse over the 6 following months.

Timeline

Start
2004-02
Primary completion
Completion
2007-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Valganciclovir Small molecule 10 mg/kg